Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Research & Development (2016 - 2025)

Tg Therapeutics has reported Research & Development over the past 10 years, most recently at $41.2 million for Q4 2025.

  • Quarterly results put Research & Development at $41.2 million for Q4 2025, up 72.54% from a year ago — trailing twelve months through Dec 2025 was $160.2 million (up 69.92% YoY), and the annual figure for FY2025 was $160.2 million, up 69.92%.
  • Research & Development for Q4 2025 was $41.2 million at Tg Therapeutics, up from $40.9 million in the prior quarter.
  • Over the last five years, Research & Development for TGTX hit a ceiling of $63.1 million in Q1 2021 and a floor of $14.8 million in Q3 2023.
  • Median Research & Development over the past 5 years was $30.7 million (2022), compared with a mean of $33.9 million.
  • Biggest five-year swings in Research & Development: plummeted 66.97% in 2023 and later surged 106.19% in 2024.
  • Tg Therapeutics' Research & Development stood at $62.6 million in 2021, then plummeted by 52.69% to $29.6 million in 2022, then tumbled by 41.12% to $17.4 million in 2023, then skyrocketed by 36.82% to $23.9 million in 2024, then surged by 72.54% to $41.2 million in 2025.
  • The last three reported values for Research & Development were $41.2 million (Q4 2025), $40.9 million (Q3 2025), and $31.8 million (Q2 2025) per Business Quant data.